RU94026082A - Применение вортманнина и его аналогов для получения препарата для ингибирования фосфатидилинозитол-3-киназы у млекопитающих и для получения препарата для лечения фосфатидилинозитол-3-киназа-зависимых состояний - Google Patents

Применение вортманнина и его аналогов для получения препарата для ингибирования фосфатидилинозитол-3-киназы у млекопитающих и для получения препарата для лечения фосфатидилинозитол-3-киназа-зависимых состояний

Info

Publication number
RU94026082A
RU94026082A RU94026082/14A RU94026082A RU94026082A RU 94026082 A RU94026082 A RU 94026082A RU 94026082/14 A RU94026082/14 A RU 94026082/14A RU 94026082 A RU94026082 A RU 94026082A RU 94026082 A RU94026082 A RU 94026082A
Authority
RU
Russia
Prior art keywords
phosphatidylinositol
kinase
preparing preparation
mammalian
treatment
Prior art date
Application number
RU94026082/14A
Other languages
English (en)
Russian (ru)
Inventor
Бонджоуклиан Розанн
Us]
Поис Гарт
Джон Влейхос Крис
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94026082A publication Critical patent/RU94026082A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
RU94026082/14A 1993-07-19 1994-07-18 Применение вортманнина и его аналогов для получения препарата для ингибирования фосфатидилинозитол-3-киназы у млекопитающих и для получения препарата для лечения фосфатидилинозитол-3-киназа-зависимых состояний RU94026082A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/094,279 US5378725A (en) 1993-07-19 1993-07-19 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US08/094279 1993-07-19

Publications (1)

Publication Number Publication Date
RU94026082A true RU94026082A (ru) 1996-05-20

Family

ID=22244209

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94026082/14A RU94026082A (ru) 1993-07-19 1994-07-18 Применение вортманнина и его аналогов для получения препарата для ингибирования фосфатидилинозитол-3-киназы у млекопитающих и для получения препарата для лечения фосфатидилинозитол-3-киназа-зависимых состояний

Country Status (16)

Country Link
US (1) US5378725A (enExample)
EP (1) EP0635268A1 (enExample)
JP (1) JPH0753370A (enExample)
KR (1) KR950002755A (enExample)
CN (1) CN1111127A (enExample)
AU (1) AU678831B2 (enExample)
CA (1) CA2128046A1 (enExample)
CZ (1) CZ283806B6 (enExample)
HU (1) HUT67667A (enExample)
IL (1) IL110325A0 (enExample)
NO (1) NO942641L (enExample)
PH (1) PH30794A (enExample)
PL (1) PL304317A1 (enExample)
RU (1) RU94026082A (enExample)
TW (1) TW287102B (enExample)
ZA (1) ZA945103B (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US7863429B2 (en) * 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
US5910417A (en) * 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US7670767B1 (en) 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
AU770896C (en) * 1998-09-29 2006-09-07 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
ATE333896T1 (de) * 1998-03-24 2006-08-15 Chugai Pharmaceutical Co Ltd Vaskularisierungsinhibitoren
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2001024826A2 (en) * 1999-10-06 2001-04-12 The Brigham And Women's Hospital, Inc. Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU6513701A (en) * 2000-05-30 2001-12-11 Advanced Res & Tech Inst Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways
US7235523B2 (en) * 2001-04-13 2007-06-26 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6703414B2 (en) * 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
CA2491555C (en) * 2002-07-10 2012-09-11 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
GB0304632D0 (en) * 2003-02-28 2003-04-02 Proxara Biotechnology Ltd Method
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
AU2004217699B2 (en) * 2003-03-07 2008-07-03 Gamida-Cell Ltd. Expansion of renewable stem cell populations using modulators of PI 3-kinase
JP2006524289A (ja) * 2003-04-23 2006-10-26 ワイス・ホールディングズ・コーポレイション Ｐｅｇ−ワートマニンコンジュゲート
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
NZ544920A (en) * 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
JP2007501836A (ja) 2003-08-13 2007-02-01 クドス ファーマシューティカルズ リミテッド アミノピロン類及びａｔｍ阻害剤としてのその使用
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
EP1799812A4 (en) * 2004-09-16 2009-09-09 Gamida Cell Ltd EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS
CN101061111A (zh) 2004-09-20 2007-10-24 库多斯药物有限公司 Dna－pk抑制剂
US7666901B2 (en) * 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
CN100369632C (zh) * 2004-10-14 2008-02-20 孔庆忠 抗癌药物组合物
CN1875959B (zh) * 2004-10-14 2010-05-12 孔庆忠 一种抗癌药物组合物
TW200638938A (en) 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AU2006214190A1 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
WO2006119569A1 (en) * 2005-05-11 2006-11-16 Genetic Technologies Limtied Methods of enriching fetal cells
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
JP2007063205A (ja) * 2005-08-31 2007-03-15 Japan Science & Technology Agency 神経因性疼痛治療剤
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
JP2010509316A (ja) * 2006-11-09 2010-03-25 ガミダ セル リミテッド 末梢血管疾患を治療するためのエクスビボ培養された造血細胞の使用
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20100109416A1 (en) * 2008-11-03 2010-05-06 Jones Margaret L Adjustable safety harness
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2011011036A (es) * 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
US20150064273A1 (en) 2012-02-13 2015-03-05 Gamida-Cell Ltd. Mesenchymal Stem Cells Conditioned Medium and Methods of Generating and Using the Same
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
CN104774239B (zh) * 2015-03-13 2017-01-04 暨南大学 多节孢绿胶霉素类化合物及其用途
CN107058137B (zh) * 2017-06-14 2020-02-07 海正药业(杭州)有限公司 一种渥曼青霉及其生产渥曼青霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
US4988682A (en) * 1989-02-03 1991-01-29 University Of Pittsburgh Myo-inositol analogs and method for their use
JPH0328948A (ja) * 1989-06-27 1991-02-07 Nec Corp 入出力制御装置の動作状態情報収集方式

Also Published As

Publication number Publication date
KR950002755A (ko) 1995-02-16
HUT67667A (en) 1995-04-28
HU9402128D0 (en) 1994-09-28
TW287102B (enExample) 1996-10-01
PL304317A1 (en) 1995-01-23
CA2128046A1 (en) 1995-01-20
CZ283806B6 (cs) 1998-06-17
JPH0753370A (ja) 1995-02-28
NO942641D0 (no) 1994-07-14
NO942641L (no) 1995-01-20
ZA945103B (en) 1996-03-27
CZ169294A3 (en) 1995-02-15
CN1111127A (zh) 1995-11-08
IL110325A0 (en) 1994-10-21
AU678831B2 (en) 1997-06-12
US5378725A (en) 1995-01-03
AU6754094A (en) 1995-01-27
EP0635268A1 (en) 1995-01-25
PH30794A (en) 1997-10-17

Similar Documents

Publication Publication Date Title
RU94026082A (ru) Применение вортманнина и его аналогов для получения препарата для ингибирования фосфатидилинозитол-3-киназы у млекопитающих и для получения препарата для лечения фосфатидилинозитол-3-киназа-зависимых состояний
RU95108243A (ru) Производные амидов вальпроновой и 2-вальпроеновой кислоты, фармацевтическая композиция, способы лечения
RU95108332A (ru) Производные индола и их таутомерные формы, смеси их изомеров и фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозин-киназы активностью и способ торможения зависящего от протеин-тирозин-киназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
RU94046306A (ru) Производные индолокарбазолимида, смесь их изомеров или отдельные изомеры и их соли и фармацевтическая композиция с активностью, ингибирующей протеинкиназу с или киназу легкой миозиновой цепи или подавляющей иммунные реакции
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
RU94041950A (ru) Использование соединений ряда 3-аролоксипропиламинов в лечении недержания
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
RU95107403A (ru) Бензоксазиноновые соединения, фармацевтические композиции, способы ингибирования обратной транскритазы, профилактики или лечения, синергистические комбинации и способ получения (-)-6-хлор-4-циклопропилэтинил-4-трифторметил-1,4-дигидро-2н-3,1-бензоксазин-2-она
IL81887A0 (en) Dihydroisoxazole derivatives,their preparation and pharmaceutical compositions containing them
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
RU95106821A (ru) Циклопептиды, способ их получения, фармацевтическая композиция и способ ее получения
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
NO994330D0 (no) Metode for behandling av en tumor
EA200100140A1 (ru) Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами
MC1930A1 (fr) Produit antiviral
CZ157795A3 (en) Pharmaceutical preparations for treating prostatitis
DE69400704D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
NO923198L (no) Terapeutiske midler
ES528461A0 (es) Procedimiento de preparacion de nuevos derivados carbamiloxibenzoles
DE69619088D1 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
RU94036666A (ru) Биостимулирующее средство